We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Recommends Bayer’s Hypertension Drug, Rejects Dosing Cap
FDA Advisory Panel Recommends Bayer’s Hypertension Drug, Rejects Dosing Cap
August 6, 2013
An FDA advisory committee Tuesday unanimously recommended approval of Bayer’s pulmonary arterial hypertension (PAH) drug Adempas, and rejected suggestions by agency reviewers that the drug only be allowed up to 1.5mg doses three times daily (TID).